These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1871 related articles for article (PubMed ID: 25975963)

  • 21. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.
    Kramer A; Stel V; Zoccali C; Heaf J; Ansell D; Grönhagen-Riska C; Leivestad T; Simpson K; Pálsson R; Postorino M; Jager K;
    Nephrol Dial Transplant; 2009 Dec; 24(12):3557-66. PubMed ID: 19820003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy.
    Merino JL; Galeano C; Espejo B; Rivera M; Fernández-Lucas M; Caldés S; Plana MN; Letosa M; Teruel JL; Quereda C; Ortuño J
    Nephrol Dial Transplant; 2011 Apr; 26(4):1360-6. PubMed ID: 20810451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of end-stage renal disease and kidney transplant outcome.
    Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
    Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis.
    Park HJ; Park JY; Jung SM; Song JJ; Park YB; Lee SW
    BMC Gastroenterol; 2019 Jun; 19(1):90. PubMed ID: 31196158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.
    Sada KE; Yamamura M; Harigai M; Fujii T; Takasaki Y; Amano K; Fujimoto S; Muso E; Murakawa Y; Arimura Y; Makino H;
    Arthritis Res Ther; 2015 Nov; 17():305. PubMed ID: 26525413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV patients.
    Arnold S; Wallmeier P; Tais A; Ihorst G; Janoschke M; Schubach F; Aries P; Bergner R; Bremer JP; Görl N; Gutdeutsch E; Hellmich B; Henes J; Hoyer BF; Kangowski A; Kötter I; Krusche M; Magnus T; Metzler C; Müller-Ladner U; Petersen J; Reichelt de Tenorio A; Schaier M; Schirmer JH; Schönermarck U; Thiel J; Unger L; Venhoff N; Weinmann-Menke J; Iking-Konert C; Lamprecht P
    Clin Exp Rheumatol; 2024 Apr; 42(4):852-858. PubMed ID: 38607682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between attributed cause of end-stage renal disease and risk of death in Brazilian patients receiving renal replacement therapy.
    Batista PB; Lopes AA; Costa FA
    Ren Fail; 2005; 27(6):651-6. PubMed ID: 16350813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis.
    Kauffmann M; Bobot M; Robert T; Burtey S; Couvrat-Desvergnes G; Lavainne F; Puéchal X; Terrier B; Quéméneur T; Faguer S; Karras A; Brunet P; Couchoud C; Jourde-Chiche N;
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1665-1675. PubMed ID: 34750159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre.
    Mun CH; Yoo J; Jung SM; Song JJ; Park YB; Lee SW
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):65-72. PubMed ID: 29465370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification.
    Deshayes S; Martin Silva N; Khoy K; Yameogo S; Mariotte D; Lobbedez T; Aouba A
    Rheumatology (Oxford); 2019 Oct; 58(10):1731-1739. PubMed ID: 30805643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway.
    Nilsen AT; Karlsen C; Bakland G; Watts R; Luqmani R; Koldingsnes W
    Rheumatology (Oxford); 2020 Sep; 59(9):2316-2324. PubMed ID: 31859355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey.
    Pamuk ÖN; Dönmez S; Calayır GB; Pamuk GE
    Clin Rheumatol; 2016 Aug; 35(8):2063-2071. PubMed ID: 26992904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.
    Sánchez Álamo B; Moi L; Bajema I; Faurschou M; Flossmann O; Hauser T; Hruskova Z; Jayne D; Luqmani R; Mahr A; Åkesson A; Westman K;
    Nephrol Dial Transplant; 2023 Jun; 38(7):1655-1665. PubMed ID: 36617233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis.
    Deshayes S; Aouba A; Khoy K; Mariotte D; Lobbedez T; Martin Silva N
    PLoS One; 2018; 13(4):e0195680. PubMed ID: 29621352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of anti-neutrophil cytoplasmic antibody-associated renal vasculitis: a retrospective study in rural and regional Victoria, Australia.
    Oakman G; Bach CA; Ong C
    Intern Med J; 2024 Mar; 54(3):461-466. PubMed ID: 37183767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of renal involvement on survival in ANCA-associated vasculitis.
    Rathi M; Pinto B; Dhooria A; Sagar V; Mittal T; Rajan R; Dhir V; Kumar S; Sharma K; Nada R; Singh S; Minz RW; Sharma A
    Int Urol Nephrol; 2016 Sep; 48(9):1477-82. PubMed ID: 27272254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.
    Casal Moura M; Gauckler P; Anders HJ; Bruchfeld A; Fernandez-Juarez GM; Floege J; Frangou E; Goumenos D; Segelmark M; Turkmen K; van Kooten C; Tesar V; Geetha D; Fervenza FC; Jayne DRW; Stevens KI; Kronbichler A
    Nephrol Dial Transplant; 2023 Oct; 38(11):2637-2651. PubMed ID: 37164940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of cyclophosphamide on the prognosis of Japanese patients with renal vasculitis associated with anti-neutrophil cytoplasmic antibody-positive microscopic polyangiitis.
    Iwabuchi M; Nakaya I; Tsuchiya Y; Shibagaki Y; Yamaguchi T; Fukuhara S; Oe Y; Sakuma T; Sato T; Taguma Y; Soma J
    Clin Exp Nephrol; 2016 Oct; 20(5):712-719. PubMed ID: 26590052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis.
    Puéchal X; Pagnoux C; Perrodeau É; Hamidou M; Boffa JJ; Kyndt X; Lifermann F; Papo T; Merrien D; Smail A; Delaval P; Hanrotel-Saliou C; Imbert B; Khouatra C; Lambert M; Leské C; Ly KH; Pertuiset E; Roblot P; Ruivard M; Subra JF; Viallard JF; Terrier B; Cohen P; Mouthon L; Le Jeunne C; Ravaud P; Guillevin L;
    Arthritis Rheumatol; 2016 Mar; 68(3):690-701. PubMed ID: 26473755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic algorithm for antineutrophil cytoplasmic antibody-associated systemic vasculitis.
    Beketova TV
    Ter Arkh; 2018 May; 90(5):13-22. PubMed ID: 30701885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 94.